Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Acta Haematol
1 Am J Hematol
1 Ann Hematol
5 Blood
3 BMC Cancer
1 Bone Marrow Transplant
1 Cell
2 Exp Hematol
1 Genes Chromosomes Cancer
2 J Clin Oncol
3 Leuk Lymphoma
3 Leuk Res
6 Leukemia
1 Oncol Rep

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. TO AQ, Ciurea SO, Kongtim P
    Acquired Factor V Deficiency: A New Cause of Bleeding in Patients with Chronic Myeloid Leukemia and Extreme Leukocytosis?
    Acta Haematol. 2022 May 2. pii: 000524630. doi: 10.1159/000524630.
    PubMed         Abstract available

    Am J Hematol

  2. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    PubMed         Abstract available

    Ann Hematol

  3. SEKERES MA, Schuster M, Joris M, Krauter J, et al
    A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
    PubMed         Abstract available


  4. BIEDERSTADT A, Rezvani K
    How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.
    Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
    PubMed         Abstract available

  5. Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
    Blood. 2022;139:2848.

  6. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    PubMed         Abstract available

  7. MACIOCIA PM, Wawrzyniecka PA, Maciocia NC, Burley A, et al
    Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
    PubMed         Abstract available

    New hope to prevent ALL relapse after transplant.
    Blood. 2022;139:2580-2581.

    BMC Cancer

  9. TOKSVANG LN, Als-Nielsen B, Bacon C, Bertasiute R, et al
    Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and ad
    BMC Cancer. 2022;22:483.
    PubMed         Abstract available

  10. WANG G, Yan G, Sang K, Yang H, et al
    Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia.
    BMC Cancer. 2022;22:481.
    PubMed         Abstract available

  11. BI Y, Wang Z, Feng S, Wang Y, et al
    Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients.
    BMC Cancer. 2022;22:477.
    PubMed         Abstract available

    Bone Marrow Transplant

  12. NAGLER A, Peczynski C, Dholaria B, Labopin M, et al
    Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
    Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01693.
    PubMed         Abstract available


    CAR T cells are in it [CD]4 the long haul.
    Cell. 2022;185:1112-1114.
    PubMed         Abstract available

    Exp Hematol

  14. KATO H, Maezawa Y, Nishijima D, Iwamoto E, et al
    A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.
    Exp Hematol. 2022;109:11-17.
    PubMed         Abstract available

  15. PAREDES R, Doleschall N, Connors K, Geary B, et al
    EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Exp Hematol. 2022;107:1-8.
    PubMed         Abstract available

    Genes Chromosomes Cancer

  16. JIANG F, Lang X, Chen N, Jin L, et al
    A Novel HNRNPH1::ERG Rearrangement in Aggressive Acute Myeloid Leukemia.
    Genes Chromosomes Cancer. 2022 May 3. doi: 10.1002/gcc.23051.
    PubMed         Abstract available

    J Clin Oncol

  17. WALSH BS, Kesselheim AS, Sarpatwari A, Rome BN, et al
    Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
    J Clin Oncol. 2022;40:1102-1110.
    PubMed         Abstract available

  18. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed         Abstract available

    Leuk Lymphoma

  19. ASOUBAR S, Esfahani A, Vahedi A, Mohammadi SM, et al
    Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
    Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
    PubMed         Abstract available

  20. PREBET T, Goldberg AD, Jurcic JG, Khaled S, et al
    A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
    PubMed         Abstract available

  21. SZCZEPANEK E, Chukwu O, Kaminska M, Wysoglad H, et al
    Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
    Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
    PubMed         Abstract available

    Leuk Res

  22. BAI H, Zhang Q, Zhang S, Wang J, et al
    Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.
    Leuk Res. 2022;117:106843.
    PubMed         Abstract available

  23. KARBALIVAND M, Almada LL, Ansell SM, Fernandez-Zapico ME, et al
    MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
    Leuk Res. 2022;116:106841.
    PubMed         Abstract available

  24. NORVILAS R, Batiuskaite R, Dirse V, Semaskeviciene R, et al
    Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL.
    Leuk Res. 2022;116:106825.
    PubMed         Abstract available


  25. BACCARANI M, Bonifazi F, Soverini S, Castagnetti F, et al
    Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.
    Leukemia. 2022;36:1227-1236.
    PubMed         Abstract available

  26. KHANLARI M, Yin CC, Takahashi K, Lachowiez C, et al
    Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Leukemia. 2022;36:1343-1350.
    PubMed         Abstract available

  27. GBYLI R, Song Y, Liu W, Gao Y, et al
    In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
    Leukemia. 2022;36:1313-1323.
    PubMed         Abstract available

  28. CAPLAN M, Wittorf KJ, Weber KK, Swenson SA, et al
    Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML.
    Leukemia. 2022;36:1296-1305.
    PubMed         Abstract available

  29. BODDICKER NJ, Achenbach SJ, Parikh SA, Kleinstern G, et al
    Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.
    Leukemia. 2022;36:1404-1407.

  30. NACHMIAS B, Khan DH, Voisin V, Mer AS, et al
    IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells.
    Leukemia. 2022;36:1283-1295.
    PubMed         Abstract available

    Oncol Rep

  31. LALIC H, Aurer I, Batinic D, Visnjic D, et al
    Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Oncol Rep. 2022;47.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.